Notícias

IONS doses first patient in the phase I/II ASCEND study of ION337, marking a key step in developing a potential disease-modifying treatment for Dravet syndrome.

Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over the course of 18 months.

Biogen Inc. (NASDAQ:BIIB) traded higher after releasing encouraging Phase 2 data for its experimental Alzheimer’s treatment, diranersen, with results showing meaningful reductions in tau pathology alongside improvements across several measures of cognitive decline.

FEATURE The artificial-intelligence trade appeared to be reignited Tuesday as investors digested a slew of bank earnings reports ahead of the consumer-price index inflation report for June. International Business Machines sank 23% after the company’s preliminary second-quarter adjusted earnings and revenue missed analysts’ targets.

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.

The decision marks a major shift in how patients can begin therapy for early Alzheimer’s disease.

A global chip sector's retreat dragged the Nasdaq lower this morning, as oil surged today, July 13, 2026.

Energy names help cushion the Dow as oil jumps on U.S.–Iran tensions and investors brace for key earnings and inflation data, today, July 13, 2026.

American Express, Biogen upgraded: Wall Street's top analyst calls

Investing.com -- Truist Securities upgraded Biogen to Buy from Hold and raised its price target to $235 from $190, citing growing confidence in the company’s Alzheimer’s and immunology pipeline ahead of several major clinical data readouts over the next two years.

Biogen stock receives a bullish upgrade based on expectations the market will cheer the company’s detailed data on its experimental Alzheimer’s drug.

Wall Street analysts handed out surprise upgrades and painful downgrades on Monday, shifting outlooks for companies ranging from a pizza chain to a crypto-adjacent fintech as second-quarter earnings season prepares to kick off against a backdrop of Iran strikes and surging Treasury yields.

Biogen will present detailed Phase 2 study data for its experimental Alzheimer’s drug diranersen at a conference in London.

A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across the RNA and rare-disease biotech space with more catalysts still ahead.

A look at the company's history of deep drawdowns shows the real risk shareholders are carrying today.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 11.5% over the past six months, topping the S&P 500 by 4.3 percentage points.

Biogen is poised to announce its second-quarter results later this month, and analysts predict a double-digit drop in the company’s bottom-line figure.

On July 8, 2026, Moderna, Inc. appointed veteran financial executive Michael McDonnell, former Biogen CFO, to its Board of Directors and Audit Committee, while a federal advisory panel previously backed approval of the company’s first-of-its-kind mRNA influenza vaccine. Together with new programs in autoimmune disease, ovarian cancer and an AI-enabled research platform, these developments highlight Moderna’s push to broaden its mRNA franchise beyond COVID-19 and seasonal respiratory...

Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th

Ionis completes enrollment in the pivotal pediatric cohort of its phase III REVEAL study, advancing obudanersen toward potential regulatory submissions.

Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.

Healthcare stocks are attractive in a choppy market. These funds, focusing on the broader sector, drugmakers, and biotechs, are worth a look.

Biogen Inc. (NASDAQ:BIIB) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 29, it was reported that Biogen is scaling back Apellis Pharmaceuticals’ research pipeline and reducing its R&D staff, weeks after completing a $5.6 billion acquisition of the company. Biogen has suspended several legacy research programs, including Phase […]

This could be a key move for future growth.

Jay Woods recommended investing in the BioTech ETF and Biogen in particular within the ETF.

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.

Biogen stock has delivered a strong 57.5% return over the past year, and with the current valuation checks painting a mixed picture rather than a clear bargain or clear overvaluation, investors are weighing how much of the recent Alzheimer’s and immunology news is already reflected in the price. Over the last 12 months, Biogen has returned 57.5%, which puts a spotlight on whether today’s share price still offers an attractive entry point or mainly reflects recent optimism. On the upside,...

Biogen (NasdaqGS:BIIB) plans to present new investigational data from its Alzheimer’s portfolio at AAIC 2026. The company will share detailed Phase 2 CELIA results for diranersen, a tau-targeting therapy. Biogen will also present real-world evidence on subcutaneous lecanemab, including usage patterns and long-term outcomes. For investors tracking Biogen, the AAIC 2026 agenda centers on two core Alzheimer’s assets that are central to the company’s neurodegeneration focus. Diranersen targets...

AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.